Trump's Drug-Pricing Agreements to Face Scrutiny with Upcoming Drug Launches
STAT+: Trump’s drug-pricing deals set to be tested by new product launches
Stat
Image: Stat
Three new drugs, Baxfendy, Awiqli, and Veppanu, will soon launch in the U.S. under President Trump's most-favored-nation pricing deals, offering insight into their pricing compared to other wealthy nations.
- 01The most-favored-nation deals require drug prices in the U.S. to align with those in other wealthy countries.
- 02Baxfendy, an AstraZeneca hypertension medication, and Veppanu, a cancer drug from Arvinas and Pfizer, will launch soon.
- 03Awiqli, an insulin product from Novo Nordisk, is also set to debut, marking a significant moment for drug pricing transparency.
Advertisement
In-Article Ad
As new drug launches approach, the public will gain insights into the pricing of medications under President Trump's most-favored-nation agreements with 17 pharmaceutical companies. These deals mandate that new drugs be introduced in the U.S. at net prices comparable to those in other affluent nations, though specific terms remain undisclosed. The upcoming launches include Baxfendy, a hypertension treatment from AstraZeneca, Awiqli, an insulin product from Novo Nordisk, and Veppanu, a cancer therapy developed by Arvinas and Pfizer, which will be licensed to Rigel Pharmaceuticals. Notably, Baxfendy and Veppanu are not yet available in the countries used for pricing comparisons. This situation presents a critical opportunity to evaluate the effectiveness and impact of Trump's drug pricing initiatives on the U.S. pharmaceutical market, as these drugs will serve as the first real-world examples of the pricing strategies resulting from these agreements.
Advertisement
In-Article Ad
The launch of these drugs may affect healthcare costs and access for U.S. patients.
Advertisement
In-Article Ad
Reader Poll
What do you think about the new drug pricing agreements?
Connecting to poll...
Read the original article
Visit the source for the complete story.
